About Pressure BioSciences, Inc. Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Forward-Looking Statements Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the test results reported by Ms. Nori, Dr. Dimsoski, and Dr. McCord on an improved method for rape kit testing using PCT; the unique ability of PCT to break one type of cell while leaving a second type of cell intact; the ability of a novel cell capture method, when used in combination with PCT, to increase the number of sperm cells in rape kit samples available for testing, resulting in a better DNA profile; that a better DNA profile might lead to more rapid identifications, increased arrests, and more successful prosecutions; the backlog of untested rape kits and that the backlog is a national travesty; that improved methods of rape kit testing might lead to reduced testing time; that new collaborations will augment and exten
|SOURCE Pressure BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved